He'll push the Q Continuum's "wonder drugs" like HCQ and IvermeQtin because he thinks they're "proven cures."
But what does the NIH know, right?
Ivermectin, ‘Wonder drug’ from Japan: the human use perspective
Andy CRUMP *1, Satoshi OMURA *1,†
Editor: Satoshi OMURA
pmc.ncbi.nlm.nih.gov
PMCID: PMC3043740 PMID: 21321478
Abstract Discovered in the late-1970s, the pioneering drug ivermectin, a dihydro derivative of avermectin—originating solely from a single microorganism isolated at the Kitasato Intitute, Tokyo, Japan from Japanese soil—has had an immeasurably beneficial impact in improving the lives and welfare of billions of people throughout the world. Originally introduced as a veterinary drug, it kills a wide range of internal and external parasites in commercial livestock and companion animals. It was quickly discovered to be ideal in combating two of the world’s most devastating and disfiguring diseases which have plagued the world’s poor throughout the tropics for centuries. It is now being used free-of-charge as the sole tool in campaigns to eliminate both diseases globally. It has also been used to successfully overcome several other human diseases and new uses for it are continually being found. This paper looks in depth at the events surrounding ivermectin’s passage from being a huge success in Animal Health into its widespread use in humans, a development which has led many to describe it as a “wonder” drug.
+++
But wait! There's more from the NIH!
pubmed.ncbi.nlm.nih.gov
. 2021 Aug 3:43:100924.
doi: 10.1016/j.nmni.2021.100924. eCollection 2021 Sep.
Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19
A D Santin 1 , D E Scheim 2 , P A McCullough 3 , M Yagisawa 4 , T J Borody 5
Affiliations
Abstract
In 2015, the Nobel Committee for Physiology or Medicine, in its only award for treatments of infectious diseases since six decades prior, honoured the discovery of ivermectin (IVM), a multifaceted drug deployed against some of the world's most devastating tropical diseases. Since March 2020, when IVM was first used against a new global scourge, COVID-19, more than 20 randomized clinical trials (RCTs) have tracked such inpatient and outpatient treatments. Six of seven meta-analyses of IVM treatment RCTs reporting in 2021 found notable reductions in COVID-19 fatalities, with a mean 31% relative risk of mortality vs. controls. During mass IVM treatments in Peru, excess deaths fell by a mean of 74% over 30 days in its ten states with the most extensive treatments. Reductions in deaths correlated with the extent of IVM distributions in all 25 states with p < 0.002. Sharp reductions in morbidity using IVM were also observed in two animal models, of SARS-CoV-2 and a related betacoronavirus. The indicated biological mechanism of IVM, competitive binding with SARS-CoV-2 spike protein, is likely non-epitope specific, possibly yielding full efficacy against emerging viral mutant strains.
Keywords: COVID-19; H. pylori; SARS-CoV-2; ivermectin; spike protein.
© 2021 The Author(s). |
